Small molecules, big impact: 20 years of targeted therapy in oncology
The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …
have led to the development of small molecule inhibitors as a major therapeutic class for …
Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy
C Pottier, M Fresnais, M Gilon, G Jérusalem… - Cancers, 2020 - mdpi.com
Receptor tyrosine kinases (RTKs) are key regulatory signaling proteins governing cancer
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
cell growth and metastasis. During the last two decades, several molecules targeting RTKs …
[HTML][HTML] Effective drug combinations in breast, colon and pancreatic cancer cells
Combinations of anti-cancer drugs can overcome resistance and provide new treatments,.
The number of possible drug combinations vastly exceeds what could be tested clinically …
The number of possible drug combinations vastly exceeds what could be tested clinically …
Targeted therapy in melanoma and mechanisms of resistance
The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …
[HTML][HTML] NRAS mutant melanoma: Towards better therapies
T Randic, I Kozar, C Margue, J Utikal, S Kreis - Cancer treatment reviews, 2021 - Elsevier
Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …
a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy …
[HTML][HTML] AKT and ERK dual inhibitors: the way forward?
Z Cao, Q Liao, M Su, K Huang, J Jin, D Cao - Cancer letters, 2019 - Elsevier
Abstract Phosphatidylinositol 3-kinase (PI3K)/AKT pathway regulates cell growth,
proliferation, survival, mobility and invasion. Mitogen-activated protein kinase …
proliferation, survival, mobility and invasion. Mitogen-activated protein kinase …
Challenges and opportunities in developing targeted therapies for triple negative breast cancer
AG Chapdelaine, G Sun - Biomolecules, 2023 - mdpi.com
Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers
characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 …
characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 …
[HTML][HTML] Strategies to tackle RAS-mutated metastatic colorectal cancer
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are
identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC) …
identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC) …
[HTML][HTML] The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis
CSE Hendrikse, PMM Theelen, P Van Der Ploeg… - Gynecologic …, 2023 - Elsevier
Abstract Background The RAS/RAF/MEK/ERK (MAPK) pathway plays a role in ovarian
carcinogenesis. Low-grade serous ovarian carcinoma (LGSOC) frequently harbors …
carcinogenesis. Low-grade serous ovarian carcinoma (LGSOC) frequently harbors …
Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients
T Pappa, S Ahmadi, E Marqusee, HL Johnson… - Clinical Cancer …, 2021 - AACR
Purpose: The extent to which routine genomic sequencing can identify relevant secondary
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …
genomic alterations among BRAFV600E-mutant papillary thyroid carcinoma (PTC) is …